1305208-47-2 Usage
Uses
Used in Organic Synthesis:
3-hydroxy-3-aminomethyloxetane is used as a synthetic building block for its versatile reactivity, allowing it to participate in a wide range of chemical reactions, which is crucial for the development of new organic compounds.
Used in Polymer Chemistry:
In polymer chemistry, 3-hydroxy-3-aminomethyloxetane is utilized as a monomer or a building block to create polymers with specific properties, taking advantage of its ability to engage in various polymerization reactions.
Used in Pharmaceutical Development:
3-hydroxy-3-aminomethyloxetane is used as a potential component in the development of pharmaceuticals, leveraging its unique structure and reactivity to create new drug candidates with therapeutic potential.
Used in Advanced Material Creation:
In the field of material science, 3-hydroxy-3-aminomethyloxetane is employed as a key component in the synthesis of advanced materials, where its properties can contribute to the creation of materials with novel characteristics for various applications.
Used in Biological Research:
3-hydroxy-3-aminomethyloxetane is used as a potential bioactive molecule in biological research, where its interactions with biological systems can lead to new insights and applications in the life sciences.
Check Digit Verification of cas no
The CAS Registry Mumber 1305208-47-2 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,0,5,2,0 and 8 respectively; the second part has 2 digits, 4 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 1305208-47:
(9*1)+(8*3)+(7*0)+(6*5)+(5*2)+(4*0)+(3*8)+(2*4)+(1*7)=112
112 % 10 = 2
So 1305208-47-2 is a valid CAS Registry Number.
1305208-47-2Relevant academic research and scientific papers
HMOX1 inducers
-
Page/Page column 127, (2020/09/18)
The present invention is related to compounds of structure (I) as heme oxygenase 1 (HMOX 1) inducers. The present invention is also related a method of controlling the activity or the amount, or both the activity and the amount, of heme-oxygenase 1 in a mammalian subject. The definitions of the variables are provided herein.
INHIBITORS OF KEAP1-Nrf2 PROTEIN-PROTEIN INTERACTION
-
Paragraph 1806, (2020/03/01)
Sultam compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with the KEAP1-Nrf2 interaction, such as inflammatory bowel disease, including Crohn's disease and ulcerative colitis.
QUINAZOLINE COMPOUND FOR EGFR INHIBITION
-
Paragraph 0210; 0212; 0222; 0224, (2019/11/21)
Disclosed is a novel quinazoline compound. Specifically, disclosed are a compound represented by the formula (I) and a pharmacologically acceptable salt.
